176 related articles for article (PubMed ID: 12922946)
1. Established criteria for disease controlling drugs in ankylosing spondylitis.
Gladman DD
Ann Rheum Dis; 2003 Sep; 62(9):793-4. PubMed ID: 12922946
[No Abstract] [Full Text] [Related]
2. Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.
Kassimos DG; Garyfallos A; Delamere J; Whallett A; Kitas GD
Rheumatology (Oxford); 2003 Mar; 42(3):490. PubMed ID: 12626807
[No Abstract] [Full Text] [Related]
3. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
4. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.
Paul S; Keat A
Rheumatology (Oxford); 2005 Jan; 44(1):17-23. PubMed ID: 15328421
[No Abstract] [Full Text] [Related]
5. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
Temel M; Atagündüz P; Direskeneli H
Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
[No Abstract] [Full Text] [Related]
6. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
Smith N; Gadsby K; Butt S; Deighton C
Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
[No Abstract] [Full Text] [Related]
7. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
[No Abstract] [Full Text] [Related]
8. Evidence in support of the validity of the TNF brake hypothesis.
Maksymowych WP
Ann Rheum Dis; 2013 Dec; 72(12):e31. PubMed ID: 23989987
[No Abstract] [Full Text] [Related]
9. [New results from studies of therapy of ankylosing spondylitis with infliximab].
Braun J
Z Rheumatol; 2003 Apr; 62(2):108-9. PubMed ID: 12820612
[No Abstract] [Full Text] [Related]
10. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
[No Abstract] [Full Text] [Related]
11. Treatment of ankylosing spondylitis with infliximab.
Boeger CA; Wittwer H; Schattenkirchner M; Kellner H; Kellner W
Ann Rheum Dis; 2001 Dec; 60(12):1159-60. PubMed ID: 11760727
[No Abstract] [Full Text] [Related]
12. Response to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych.
Baraliakos X; Braun J
Ann Rheum Dis; 2013 Dec; 72(12):e32-3. PubMed ID: 24058016
[No Abstract] [Full Text] [Related]
13. [The role of biologic agents in the therapy of ankylosing spondylitis].
Géher P; Nagy MB; Péntek M; Tóth E; Brodszky V; Gulácsi L
Orv Hetil; 2006 Jul; 147(26):1203-13. PubMed ID: 16898082
[TBL] [Abstract][Full Text] [Related]
14. Assessment of soluble cell adhesion molecules and soluble CD40 ligand levels in ankylosing spondylitis.
Sari I; Alacacioglu A; Kebapcilar L; Taylan A; Bilgir O; Yildiz Y; Yuksel A; Kozaci DL
Joint Bone Spine; 2010 Jan; 77(1):85-7. PubMed ID: 20022783
[No Abstract] [Full Text] [Related]
15. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
[No Abstract] [Full Text] [Related]
16. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Ann Rheum Dis; 2014 May; 73(5):941-3. PubMed ID: 24323393
[No Abstract] [Full Text] [Related]
17. [Biological treatment of ankylosing spondylitis].
Freiesleben S; Schou M
Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
[TBL] [Abstract][Full Text] [Related]
18. Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis.
Zochling J; Braun J
Expert Opin Pharmacother; 2006 May; 7(7):869-83. PubMed ID: 16634710
[TBL] [Abstract][Full Text] [Related]
19. Ankylosing spondylitis: new treatment modalities.
Brandt J; Marzo-Ortega H; Emery P
Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):559-70. PubMed ID: 16777582
[TBL] [Abstract][Full Text] [Related]
20. Biologic agents for treating ankylosing spondylitis: beyond TNFα antagonists.
Wendling D; Prati C
Joint Bone Spine; 2011 Dec; 78(6):542-4. PubMed ID: 21803631
[No Abstract] [Full Text] [Related]
[Next] [New Search]
